Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna to Report Q2 Earnings: Is a Beat in Store for the Stock?

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline milestones.

MRKPositive Net Change MRNAPositive Net Change EXASPositive Net Change BNTXPositive Net Change

Zacks Equity Research

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change